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ABSTRACT For the isolation ofcDNA clones encoding the
carcinoembryonic antigen (CEA), we have constructed a cDNA
library from human colon tumor mRNA. The library was
screened with various oligonucleotides whose sequence had
been deduced from partial amino acid sequence data for CEA.
Positive candidate clones were hybridized with a probe for
repetitive DNA, because CEA mRNA contains anAlu repetitive
element, and with a fragment of a genomic clone of nonspecific
cross-reacting antigen, an antigen closely related to CEA. Here
we report the nucleotide sequence of the two overlapping CEA
cDNA clones comprising 1422 nucleotides ofCEA mRNA. This
sequence encodes the 372 COOH-terminal amino acids of CEA
followed by 305 nucleotides of 3' untranslated sequence con-
taining a truncated Alu repeat. The predicted protein sequence
is composed of two repeats comprising 178 amino acids, each
with an exceptionally high homology of 67%. Each repeat unit
contains four conserved cysteine residues and six to nine
putative N-glycosylation sites. CEA mRNA is most strongly
expressed in primary colon tumors and, to a lesser extent, in
normal colonic tissue. No CEA mRNA is found in HeLa cells
and normal human fibroblasts.
One of the most widely used human tumor markers is the
carcinoembryonic antigen (CEA). Although this oncodevel-
opmentally regulated antigen lacks absolute tumor specific-
ity, the CEA concentration in sera of cancer patients is an
important parameter in the surveillance of patients in the
postoperative phase (1). The presence ofCEA on tumor cells
has been exploited for immunolocalization ofprimary tumors
and their metastases (2) and for immunotherapy without (3)
and with drug targeting (4).
CEA is a heterogenous highly glycosylated protein with a
molecular weight of -180,000. Highest tissue concentrations
are found in adenocarcinomas of the digestive system and in
fetal colon. It is encoded by an mRNA of =3100 nucleotides
and is synthesized as an 80-kDa precursor protein (5). There
are some indications that a tumor-specific CEA molecule
might exist among the different CEA variants, which is
associated only with malignant diseases (6). Recent findings
suggest that lung and breast tumors might also contain
tissue-specific CEA species (7). In addition to CEA, there are
a number of immunologically closely related antigens (e.g.,
nonspecific cross-reacting antigen or NCA), which vary in
size (8) and tissue distribution (9). These cross-reacting
antigens are encoded by separate genes, as implied by their
very similar but distinct NH2-terminal amino acid sequences
(10).
To define more precisely the various members of the CEA
family and to investigate the role of CEA in ontogenesis and
in malignancy, we have cloned CEA mRNA. In the present
study, we describe the nucleotide sequence of two overlap-
ping CEA cDNA clones (pCEA1 and pCEA2) comprising
1422 nucleotides of the CEA mRNA, the composition of the
encoded polypeptide of two large and very closely related
repeats, and the expression ofCEA mRNA in various normal
and tumorous tissues and cell lines.
MATERIALS AND METHODS
Tissues and Cell Lines. After surgical resection, primary
human colon adenocarcinomas and nontumorous colonic
tissue were separated, frozen, and stored in liquid nitrogen.
For some experiments, a human colon carcinoma was used
that had been propogated and amplified in athymic mice (11).
The colon tumor cell lines SW403 (a gift from J. Shively,
Duarte, CA) and LoVo (American Type Culture Collection)
were grown in RPMI medium with 10% fetal calf serum and
in F-12 medium with 20% fetal calf serum, respectively. The
cells were stored in liquid nitrogen until used for RNA
isolation.
Construction of a Colon Tumor cDNA Library. Poly(A)+
RNA was isolated from a human colon tumor grown in
athymic mice (11) according to a method developed by
Fiddes and Goodman (12), as described (13). cDNA synthe-
sis, dC-tailing of double-stranded cDNA, and annealing with
Pst I linearized and dG-tailed pBR322 (New England Nucle-
ar) were performed essentially as described by Gubler and
Hoffman (14). The recombinant plasmids were transfected
into competent bacteria of the Escherichia coli strain
RRlAM15 (15) using the protocol of Hanahan (16). About
5000 independent recombinant clones were established on
nitrocellulose filters and grown overnight on agar plates in the
presence of tetracycline. The colonies were rinsed off the
filters with LB and the bacteria were pelleted, resuspended
in LB containing 50% (vol/vol) glycerol, and stored at
-700C.
Screening of the cDNA Library. Recombinant clones of the
colon tumor cDNA library were grown on nitrocellulose
filters, amplified in the presence of chloramphenicol, and
screened with synthetic oligonucleotides (provided by J.
Shively), essentially as described (17). The sequences of the
synthetic oligonucleotides between 42 and 54 nucleotides
long (18) had been deduced from partial CEA andNCA amino
acid sequences (19) by using a method published by Lathe
(20). Colony hybridization with the 32P-labeled oligonucleo-
tides was performed in the presence of 1.08 M NaCl at
temperatures 20°C below the melting temperatures calculated
for the different oligonucleotides (20). The final stringent
wash was in 2x SSPE (lx SSPE = 0.18 M NaCl/10 mM
sodium phosphate, pH 7.4/1 mM EDTA)/0.5% NaDodSO4
Abbreviations: CEA, carcinoembryonic antigen; NCA, nonspecific
cross-reacting antigen.
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for 15 min at 20C-40C below the calculated melting temper-
atures.
Positive colonies were subjected to a second round of
screening; they were hybridized either with 32P-labeled
human DNA used as a probe for repetitive sequences (21) or
with a 1.4-kilobase (kb) EcoRI fragment from the genomic
clone X39.2 of a human NCA gene that had been subcloned
in pUC18 [obtained from J. Thompson and J. Shively (18)].
After hybridization, the colony filters were washed under
moderately stringent conditions in 2x SSPE/0.5% NaDod-
S04 (human repetitive probe) or at high stringency in 0.1x
SSPE/0.5% NaDodSO4 at 650C for 60 min.
RNA Blot Hybridization. Total RNAs or poly(A)-contain-
ing RNAs were size-fractionated by electrophoresis on a
denaturing methylmercury hydroxide agarose gel. The gel
was prepared for transfer ofRNA to nitrocellulose according
to a procedure described by Alwine et al. (22). Hybridization
with the cDNA inserts of pCEA1, labeled by random
hexanucleotide priming (23), was carried out as described
(24). The bands on the autoradiographs were quantitated with
an LKB 2202 Ultroscan laser densitometer in connection
with an LKB 2200 recording integrator.
DNA Sequencing and Sequence Analysis. Sequencing of
cDNAs was performed by the chemical degradation method
described by Maxam and Gilbert (25) and by the dideoxy-
chain-termination method of Sanger et al. (26). For compar-
ison of nucleotide and amino acid sequences, the EMBL
nucleotide sequence data bank,* the Protein Identification
Resource,t and the Newat 85 protein sequence library
obtained from R. R. Doolittle (San Diego, CA) were used.
For calculation of the homology of the CEA amino acid
repeats, logarithm of odds matrix scores -8 and structure
genetic matrix scores :a5 (27) were taken as conservative
exchanges.
RESULTS
Isolation of Human CEA cDNA Clones. For isolation of
cDNA clones encoding CEA and closely related antigens, we
constructed a cDNA library from colon tumor RNA. CEA
mRNA comprised 0.25-0.5% of total RNA, as shown by in
vitro translation and immunoprecipitation of the CEA pre-
cursor protein (13). A total of 20,000 cDNA colonies repre-
senting 5000 independent clones were screened by hybrid-
ization with six different synthetic oligonucleotides (18).
Their sequences had been deduced from partial amino acid
sequences ofCEA and the closely related antigen NCA (19).
Of the 120 positive colonies identified, none hybridized with
more than one oligonucleotide. We therefore assayed the
candidate clones in a second round of selection for the
presence of repetitive sequences, because CEA mRNA
contains an Alu-type repeat (28). Of these candidate clones
selected by hybridization with oligonucleotides, 23 hybrid-
ized with total human DNA used as a probe for repetitive
sequences (21). Seven of the clones positive with the repet-
itive probe hybridized with oligonucleotide 1, and 13 hybrid-
ized with oligonucleotide 2. At this stage of screening, we
obtained subcloned fragments of X39.2, which contains part
of a human NCA gene (18). A 1.4-kb EcoRI fragment of this
genomic clone containing the region complementary to oli-
gonucleotide 2 was chosen for hybridization with the clones
preselected by hybridization with the six different oligonu-
cleotides. Thirty positive clones were obtained. As expected,
all of these clones had been selected by hybridization with
oligonucleotide 2. Eight of the most strongly hybridizing
colonies were colony-purified and their plasmids were iso-
lated. All recombinant plasmids contained identical cDNA
inserts when released from the vector by digestion with Pst
I. They were designated pCEAl. One clone, designated
pCEA2, was selected that hybridized with the 1.4-kb EcoRI
fragment of the NCA clone and with human repetitive
sequences. The cDNA of this clone was expected to further
extend the CEA cDNA sequence toward the 3' end of the
mRNA, assuming the Alu sequence to be present in the 3'
nontranslated region, as has been reported for other mRNAs
(29-31).
Nucleotide Sequence of the Human CEA cDNAs. The extent
of overlap of pCEA1 and pCEA2 was determined by restric-
tion endonuclease mapping and sequencing (Fig. 1B). Suit-
able DNA fragments were subcloned and sequenced accord-
ing to the strategy shown in Fig. 1B. The nucleotide sequence
is presented in Fig. 1C. The sequence can be translated into
one open reading frame comprising the 372 COOH-terminal
amino acids. Comparison of the deduced amino acid se-
quence with sequences obtained from CEA and NCA pep-
tides (19) clearly identifies pCEA1 and pCEA2 as CEA rather
than NCA cDNA clones (data not shown). The putative
COOH-terminal polypeptide ofCEA is composed oftwo very
closely related repeats of 178 amino acids having 67% of their
amino acids in common (Fig. 2A). If one allows for conserv-
ative exchanges, the homology increases to 87%. The high
degree of homology is also obvious at the nucleotide level.
Eighty percent of the nucleotide sequences of the repeats are
identical. Due to the presence of the repeating units, oligo-
nucleotide 2, which was used for the initial screening,
hybridizes with two different regions in pCEA1 and with one
in pCEA2, showing 71% and 74% homology, respectively
(Fig. lA). The degree of homology is significantly lower than
expected [85% (20)]. This is due to the differences between
the amino acid sequence of the peptide from which the
nucleotide sequence of oligonucleotide 2 was deduced and
the amino acid sequences of the corresponding regions of
repeats a and b (Fig. LA). However, this homology was
significant enough to yield strong hybridization signals with
positive clones (data not shown). The repeat most proximal
to the COOH terminus is followed by a unique hydrophobic
sequence of 27 amino acids.
The region of CEA that is encoded in pCEA1 and pCEA2
contains 15 putative N-glycosylation sites (Asn-Xaa-Thr;
Fig. 1C), which are clustered around the cysteine residues
(Fig. 1B). This rather large number ofglycosylation sites is to
be expected when taking into account the 60% carbohydrate
content of mature CEA (33), whose oligosaccharide chains
are all linked to asparagine via N-glycosidic bonds (34).
The 3' nontranslated region of CEA mRNA contains part
of an Alu-type repetitive sequence (Fig. 1 B and C) as
predicted by the observation that two unrelated cDNA clones
containing Alu repeats hybridize with CEA mRNA (28).
Human Alu DNA is a head-to-tail dimer of two similar
sequences of -130 base pairs (bp). Both monomers can be
distinguished by the presence of a 31-bp insert in the right
repeat (35). By this criterion, only part of an Alu repeat is
present in CEA mRNA, with the left monomer being trun-
cated at the 5' end.
Comparison of the nucleotide sequence and the deduced
amino acid sequence of pCEA1 and pCEA2 with sequence
data banks did not reveal any significant homology to other
sequences.
RNA Blot Analysis of CEA mRNA Expression. The cDNA
fragments of pCEA1 were used for hybridization with blots
of size-fractionated total RNA isolated from normal and
tumorous cells and tissues. As shown in Fig. 3, the cDNA of
plasmid pCEA1 hybridizes to two mRNA species of 3500 and
*European Molecular Biology Laboratory (1985) EMBL Nucleotide
Sequence Data Library (Eur. Mol. Biol. Lab., Heidelberg, F.R.G.),
Release 7.
tProtein Identification Resource (1986) Protein Sequence Database
(Natl. Biomed. Res. Found., Washington, DC), Release 8.0.
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A
CEA peptide N D A G S Y E C E I Q N P A
derived mRNA sequence 5'- AAU GAU GCU GGC UCC UAU GAA UGU GAA AUU CAG AAC CCA GCC -3'
oligonucleotide 2 3'- TTA CTA CGA CCG AGG ATA CTT ACA CTT TAA GTC TTG GGT CGG -5'
repeata pos. 167 ...... .AT ..T G
.
... .. C .
... .
CT. AAT
repeat b pos. 701. G.....T T.TC.A C . A.. AC
B
pCEA12 1 I I I
5' C *~ C C C C C C C
repat*.-repeat
. . .2 1 1II rI I I
* e~ e e
pCE2 IIt I I I I ItC rCtYIC
C
.~~~-.. -****
1 CAACTCCAACCCCGTGCAGGATGAGGATGCTGTAGCCTTAACCTGTCAACCTGAGATTCAGAACACAACCTACCTGTGGTGGGTAAATAATCAGAGCCTCCCGGTCAGTCCCAGGCTGCA
1 AsnSerAsnProV lGI uAsp~l uAspAlaValAlaLeuThrCysGl uPro~l uxleGlwsnThr7-hzlryrLouTrpTrpValAsr4s~lne euProVal SerProArgLeuGln
** *-* -
121 GCTGTCCAATGACAACAGGACCCTCACTCTACTCAGTGTCACAAGCAATGATGTAGGACCCTATGAGTGTGCAATCCACAACGAATTAACTGTTGACCACAGCGACCCAGTCATCCTCAA
41 LeuSerA~nAmpg~nr~h &uThrLeuLeuSerValThrArgAsnAspVal~lyProTyr~l uCys~lyZIl GlnAsn~l uLeuScrValAspHisSerAspProV lZIleLeuAsn
2 41 TGTCCTCTATGGCCCAGACGACCCCACCATTTCCCCCTCATACACCTATTACCCTCCAGGGGTGAACCTCAGCCCTCTCCTGCCATGCAGCCTCTAACCCACCTCCACACTATTCTTGGCT
81 ValLeullyrGlyProA&,pAspProllhrIl eSerProSer~yrThrTyr~lyrArgPro~lyVa*lsn-LeuSe-zeuSerCyosHsAla*Ala*SerAsnProProAlaGlnTyrSer~rpLeu
361 GATTGATCGGAkACATCCAGCkACACkCACkAGAGCTCTTATCTCCAACATCACTGAGAAGkkCAGCGGACTCTATACCTGCCAGGCCkATAACTCAGCCAGTGGCCACAGCAGCACTAC
121 IlZeA~p~lyAsnZII Gln~lntfi&ThrOln~l uLouPhb-Il-S-isZ le~Fl uLysJAsnSer~lyLeuTyrThrCys~lnAl JsnAsnSeol *SerGly~isSerArgThrThr
repeat b
481 AGTCAACACAATCACAGTCTCTGCCGAGCTGCCCAAGCCCTCCATCTCCACCAACAACTCCAAACCCGTGGAGGACAAGGATGCTGTGGCCTTCACCTCTGAACCTGAGGCTCAGAACAC
161 ValLysThr~l eTbrValSerAl*CluLeuProLysProSerZIeSerSezsnsnosysProVal~l uAspLysAmpAla*V lAla*PheThrCys~l uPro~l uAla~lisn~hrF
601 AACCTACCTGTGGTCGGTAAATGCTCAGAGCCTCCCAGTCAGTCCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCTCACTCTATTCAATGTCACAAGAAATGACGCAAGAGCCTATGT
201 Tyr euTrpTrpValAsn~lyGlnSerLeuProValSerProArgLeuG.lnLeuSerAsn~llis-nA-r-T-hizaurhrLeuPhgisn val-Th-,ArgAsnAspAla*ArgAl*TyrV l
721 ATGTGGAATCCAGkACTCAGTGAGTGCkAACCGCAGTGACCCAGTCACCCTGGATGTCCTCTATGGGCCGGACACCCCCATCATTTCCCCCCCAGkCTCGTCTTACCTTCGGGAGCGkA
241 CyaGlyIer GonAsnSerValSerAl asnArgSerhspProVal ThrLeuAIpValLeuTyrlyProAspThrProlleleSerProProAspSerSerTyrLAuSerGlyAloAsn
8 41 CCTCAACCTCTCCTGCCACTCGGCCTCTAACCCATCCCCGCAGTATTCTTGGCGTATCAATGGGATACCGCAGCAACACACACAAGTTCTCTTTATCGCCAAAATCACGCCAAATAATAA
281 Le14snleuSo^ HJi sSerAl*Sezgs-nPr-oS-eilroGlZn7yrSerTrpArgIl eAsnGlyZlZeProGlnGlnNisThrGlnValLeuPhe~lleAla*Lys~leThrProAsnAsni-
.*nd repeat b
961 CGGGACCTATGCCTGTTTTGTCTCTkkCTTGGCTACTGGCCGCkATALATTCCATAGTCAAGAGCATCACAGTCTCTGCATCTGGkkCTTCTCCTGGTCTCTCAGCTGGGGCCACTGTCGG
321 GlyThi yrlaCysPheValSerAsnLeuAla*ThrGlyArdtsnAsn-Sertlr eValLysSerZIleThrV lSerAl *SerGlyThrSerProGlyLeuSerAl *ClyAl aThrVal~ly
1081 CATCATCATTGGAGTGCTGGTTGGGGTTGCTCTGATATAGCAGCCCTGGTGTAGTTTCT'TCATTTCAGGAAGACTGACAGTTGTTTGCTTCTTCCTTAAAGCATTTGCAACAGCTACAG
361 IleaetalpGlyyValLeuVlGlyVnlArlLull***
1201 TCTkkUATTGCTTSCTTTACCkAGGATATTTACAkAkUAGACTCTCkCCAGAGATCCkGACCATCCTAGCCkACATCGTCkkCCCCATCTCTACTkkkkAT'ACkkAAUTGAGCTGGGCTT
* ~ ~ rpa* . * * * *.
1321 GGTGGCGCGCACCTGTAGTCCCAGTTACTCGGGAGGCTGAGGCAGGACkATCGCTTCkACCCGGGAGGTGGAGATTGCCAGTGAGCCCAGATCGCACCACTGC
FIG. 1. (A) Aniino acid sequence (designated by the single-letter code) of a CEA peptide and the deduced nucleotide sequence of
oligonucleotide 2, which is complementary to CEA mRNA (19). The nucleotide sequence of oligonucleotide 2 is compared to the homologous
sequences of repeats a and b of CEA cDNA. Dots denote identical bases. Numbers indicate positions of the first nucleotide of the CEA cDNA
region that is homologous to oligonucleotide 2. (B) Structure of the overlapping CEA cDNA clones pCEA1 and pCEA2. A restriction map of
various endonuclease sites is shown. For the restriction endonucleases Hae III. Hpa II, and HinfI, only the sites relevant for sequiencing are
included. The Pst I sites flanking the cDNA fragments are artificially created by the cloning procedure. Direction and extent of sequence analysis
are indicated by arrows. Sanger (e) and Maxam-Gilbert (o) sequencing protocols were used. Below the sequencing strategy, several features
of the CEA mRNA are summarized graphically. Open boxes symbolize repeats aand b of the coding region. The positions of the cysteine residues
are indicated by C, and the locations of the putative N-glycosylation sites are indicated by Y . Hatched box depicts the unique hydrophobic COOH
terminus of CEA. The truncated Alu sequence in the 3' noncoding region is shown as a stippled box. (C) Nucleotide sequence and predicted
amino acid sequence of the human CEA cDNA clones pCEA1 and pCEA2. The putative N-glycosylation sites are boxed. The Alu sequence
in the 3' nontranslated region is underlined.
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A .
repeat a ------ NSNPVEDEDAVALTCEPEIQNTTYLWWVNNQSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNELSVDHSDPVIL
repeat b AELPKPSISSN ..K... ......F.A..G .... FN. ARA.V... SV.ANR.... T.
** 0* * * *
a NVLYGPDDPTISPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTTVKTITVS
b D. T.I . PDSS.LS.A..N ....S.... SP... NR.N.IP.V ... VAK. .PN.N.T.A.FVS.L.T.RNNSI ..S....
B
repeat b
NFA-1
AELPKPSISS
..P.. .F.T.
FIG. 2. (A) Comparison of repeats a and b of the predicted amino acid sequence encoded by pCEA1 and pCEA2. Identical residues are
indicated by dots. Dashes denote region of repeat a that is missing in pCEA1. The presence of a sequence similar to the homologous region
of repeat b is inferred from amino acid sequence data (R. Paxton, personal communication). (B) Comparison of the NH2-terminal regions of
repeat b of CEA with the NH2 terminus of NFA-1 (32). Dots denote identical residues. Amino acids are identified by the single-letter code.
3000 nucleotides, the smaller species being 5-fold more
abundant than the larger species. CEA mRNA is most
strongly expressed in human primary colon tumors tested
either directly after resection or after passage through
athymic nude mice (Fig. 3A). CEA mRNA is found to a lesser
extent in the colon tumor cell lines LoVo and SW403 and in
nontumorous colonic tissue from colon tumor patients (Fig.
3B). No hybridization was detected with poly(A)-containing
RNA isolated from HeLa cells and normal human fibroblasts
(data not shown).
DISCUSSION
Here we describe the isolation and characterization of two
overlapping CEA cDNA clones. The most striking feature of
the CEA mRNA is the repeated nature of the coding region
so far identified. The open reading frame encoded in pCEA1
and pCEA2 consists of two very closely related repeats
containing 178 amino acids, each without any deletion or
insertion. Both repeats share 67% of their amino acid se-
quence. This exceptionally high conservation of the amino
acid sequence of CEA is much more pronounced than in
other vertebrate proteins composed of repeated domains.
Generally, the homology of internal repeats of vertebrate
proteins is only 20-40% [e.g., human low density lipoprotein
receptor (29), human a1 B-glycoprotein (36), and human
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FIG. 3. Analysis of CEA mRNA in normal and tumorous colon
tissues and colon tumor cell lines. Two micrograms ofpoly(A)+ RNA
(A) or 10 4Atg of total RNA (B) was separated on a 1% agarose/meth-
ylmercury hydroxide gel by electrophoresis. The RNA was trans-
ferred to nitrocellulose, and the filters were hybridized with 32p_
labeled cDNA inserts of pCEAl. The RNAs had been isolated from
primary colon tumors (A, lanes 2-4) of various patients (indicated by
the letters above lanes), from a primary colon tumor propagated in
nude mice (A, lane 1; B, lane 3), from the colon tumor cell lines
SW403 (B, lane 1) and LoVo (B, lane 2), or from normal colonic tissue
from a colon tumor patient (B, lane 4). The high molecular weight
bands in lanes 2 and 4 in B are due to unspecific binding of the probe
to DNA present in these RNA preparations. The numbers on the left
indicate the size (in kb) and positions of marker DNAs and RNAs.
fibronectin repeats I and III (37)]. To our knowledge, the
highest homology between internal repeats observed to date
exists between the two type II repeats in human fibronectin
[50% (37)] and in the two repeats within human transferrin
[45% (38)]. Normally, the length of internal repeats is rather
short, varying between 40 and 95 amino acids (39). The
human transferrin and albumin, however, are composed of
repeated domains of 360 and 195 amino acids, respectively
(39). With a repeat length of 178 amino acids, CEA belongs
to this class of proteins with internal repeats.
The high degree of homology between the CEA repeats is
even more pronounced at the nucleotide level. The strong
conservation of both amino acid and nucleotide sequences
implies that the CEA gene evolved rather recently in evolu-
tion by duplication of a primordial gene. Even more recently,
the various very closely related members of the CEA gene
family, comprising about one dozen genes (18), must have
arisen by further gene duplication or exon shuffling (40). This
model was already proposed by Grunert et al. (8), who
reported that CEA and related antigens are probably com-
posed of various numbers of similar domains as evidenced by
the almost identical fingerprints of two CEA and three NCA
species having molecular weights between 50,000 and
180,000. The presence of closely related repeats in CEA
explains the finding that some monoclonal anti-CEA anti-
bodies bind to two or more epitopes on the same CEA
molecule (ref. 41; K. Schwarz, personal communication). At
present, the total number of repeats contained within CEA is
not known. However, the presence of probably three 178-
amino acid repeats can be expected, taking into account the
size of the unglycosylated CEA precursor [-700 amino acids
(5)], amino acid sequence data (19), and the length of the
unique NH2-terminal sequence ofa closely related NCA gene
[107 amino acids (18)]. It is interesting to note that the repeats
identified by CEA cDNA sequencing might be identical with
protease-resistant domains of CEA or related antigens. The
NH2-terminal amino acid sequence of the normal fecal
antigen 1 (NFA-1), a protein closely related to CEA (32),
shares 70% homology with the region of the NH2-terminal
sequence of the repeat unit of CEA (Fig. 2B). NFA-1 has a
molecular weight of 20,000-30,000 and might be a naturally
occurring degradation product of a larger CEA-related anti-
gen (32).
In each repeat, the positions of four cysteine residues are
conserved and nearly equidistant (39-47 amino acids be-
tween the residues), implying a very similar three-dimension-
al structure of both protein domains with regularly spaced
folds. In contrast to the strongly conserved positions of the
cysteine residues, the number and location of the N-
glycosylation sites are poorly conserved, with only two sites
being at homologous positions within the repeats. This lack
of conservation ofhomologous N-glycosylation sites has also
been reported for immunoglobulins and other plasma
glycoproteins composed of repeating domains (36).
Although most of the CEA (80%) is associated with the
membrane fraction (42), it is still disputed whether CEA is an
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integral membrane protein or not, By ultrastructural studies,
CEA has been located primarily in the intestinal glycocalyx
(43). The presence of a hydrophobic COOH-terminal region
of the putative CEA polypeptide suggests that the CEA
encoded by pCEA1 and pCEA2 is anchored in the plasma
membrane with an extracellular orientation of the NH2
terminus. The latter is inferred by the observation that CEA
can be labeled by the lactoperoxidase method on the surface
of intact colon tumor cells (R. Bhardwaj, personal commu-
nication).
There is one methionine residue in the unique COOH-
terminal region. Until now, the absence of methionine from
CEA, as demonstrated, e.g., by the resistance of CEA to
cyanogen bromide cleavage (44), was used as one of the
identification criteria of CEA (45). Our data predict that
cyanogen bromide treatment of CEA would release a 10-
amino acid fragment from the COOH terminus of CEA. This
small peptide pould be easily missed by conventional protein
analysis. `
The 3' untranslated region of CEA mRNA contains a
truncated Alu repeat sequence. With >300,000 copies pres-
ent per haploid genome, Alu sequences are the most abun-
dant family of human repetitive DNA sequences (35). The
dispersal of Alu elements throughout gene regions has been
reported for a number of genes (35). However, to date only
a few mRNAs have been found to carry Alu sequences. The
mRNAs for the human low density lipoprotein receptor (29),
the human p53 cellular tumor antigen (30), and the murine
class I histocompatibility antigen of the D region (31) contain
one or more Alu monomers or dimers exclusively in the 3'
untranslated region. At present, it is not known whether
repetitive sequences in mRNAs or in the genome have a
function (35).
CEA mRNA is expressed in a tissue-specific manner. We
observed no expression in HeLa tumor cells or normal
human fibroblasts, whereas colonic tissues and cell lines
contain CEA mRNA. The highest levels of CEA mRNA are
found in primary colon and rectum carcinomas. Adaptation
to growth in athymic nude mice does not change the CEA
gene expression significantly. However, establishment of
primary tumors as cell lines strongly reduces the CEA mRNA
content. The relatively strong expression of CEA mRNA in
normal colonic tissue is somewhat surprising, although CEA-
like antigens have been identified in normal colonic mucosa
(46) or in colon lavages of healthy individuals (47). Whether
this relatively high level of CEA mRNA observed in normal
colonic tissue of tumor patients is due to inflammation or to
the presence of tumor cells not visible macroscopically in
areas surrounding the tumor remains to be established.
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